Active immunisation against hepatitis A
Adult: Single dose of 0.5 ml or 1 ml depending on the product and the age of the patient. Booster dose is usually given 6-12 mth after the initial dose. To be given via SC admin in haemophiliacs.
Child: Same as adult.
|Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.
Warnings / Precautions
|Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation.
|Transient soreness, erythema, induration at inj site. Fever, malaise,
Potentially Fatal: Anaphylaxis.
|Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.
See Below for More vaccine, hepatitis a Drug Interactions
Mechanism of Actions
|Hepatitis A antigen is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. It is used for active immunisation against hepatitis A infection.
Hepatitis A Vaccine
Hepatitis A Vaccine Containing Brands
Hepatitis A Vaccine is used in following diseases
Drug - Drug Interactions of Hepatitis A Vaccine
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor